This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ocular/ Adnexal Tumors  • Alert me on articles by topic

Long-term Administration of Topical Interferon Alfa-2 in the Treatment of Conjunctival Squamous Papilloma

Arch Ophthalmol. 2003;121:1052-1053.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Interferon alfa-2 is a well-known antiviral therapy with potent antiproliferative properties. Presumably, this has been the basis for its intralesional and short-term topical administration for squamous papillomas. Like other modalities used to treat these lesions, recurrence has been common with interferon therapy. However, recent evidence suggests that long-term administration of interferon alfa-2 is capable of inhibiting angiogenesis. Clinically, it has been used in this manner, for an 8-month duration, to successfully treat various vascular tumors such as hemanigomas, Kaposi sarcoma, and hemangiopericytomas¹ as well as ocular surface neoplasia.² We report the use of long-term topical therapy (8 months) with interferon alfa-2 in the successful treatment of recurrent squamous papilloma.

Report of a Case

A 27-year-old, healthy, white man complained of an enlarging itchy "lump" in the corner of his right eye. The patient had no significant medical history. His best-corrected visual acuity was 20/15 OU. Surrounding adnexa were unremarkable and there were no signs . . . [Full Text of this Article]

Comment
Corresponding author and reprints: Lee A. Wiley, MD, Department of Ophthalmology, West Virginia University School of Medicine, PO Box 9193, Morgantown, WV 26506 (e-mail: lwiley@hsc.wvu.edu).